Histopathological assessment of residual retroperitoneal mass removed in patients after chemotherapy for non-seminomatous germ cell tumours of the testis.
نویسندگان
چکیده
Between 1990 and 1999, 182 men were treated for non-seminomatous germ cell testicular tumours. In 24 of them after chemotherapy a residual retroperitoneal mass was removed. In 14 of them additional immunohistochemical (IHC) examinations using antibodies against cytokeratins, vimentin, PLAP, CD30, AFP, βhCG, p53, and MIB-1 were performed. We compared the results of those additional studies with the results of routine histopathological examination. Histological assessment revealed most frequently (ca. 54% of cases) non-neoplastic lesions, i.e. fibro-cystic, necrotic or inflammatory tumours and lymphatic tissue. In about 33% of cases, surviving live neoplastic cells were found.
منابع مشابه
Post-chemotherapy residual mass in non-seminomatous testicular cancer. The role of retroperitoneal lymph node dissection.
PURPOSE To determine the role of RPLND for residual masses following chemotherapy in patients with non-seminomatous germ cell tumors (NSGCT) stage T1N2 and T1N3 (IIB and IIC). MATERIALS AND METHODS We have preformed retrospective analysis of 11 patients who underwent RPLND for residual masses following chemotherapy in an oncologic reference center between January 1997 and December 2002. All p...
متن کاملRole of chemotherapy prior to orchiectomy in metastatic testicular cancer—is testis really a sanctuary site?
A germ-cell tumour (GCT) of the testis is a chemosensitive tumour with high cure rates even in advanced disease. Radical inguinal orchiectomy is the initial procedure used to diagnose it which helps to risk-stratify these patients. However, in patients with life-threatening metastases, primary chemotherapy was attempted in a few studies, followed by delayed orchiectomy. The aim of this review i...
متن کاملActual developments in European regula- tory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe? introduction
non-seminomatous germ cell tumors who undergo post-chemotherapy RPLND for small tumors. J Clin Oncol 2011; 29 (abstr 224). 19. Ehrlich Y, Brames MJ, Beck S et al. Long-term followup of cisplatin combination chemotherapy in patients with disseminated non-seminomatous germ cell tumors: is a post-chemotherapy RPLND needed after complete remission? J Clin Oncol 2010; 28: 531–536. 20. Kollmannsberge...
متن کاملFDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment
The value of F-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in detecting viable tumours in patients with metastasised non-seminomatous testicular cancer and residual and new masses post chemotherapy remains to be determined. We describe the case of a 41-year-old patient with metastasised non-seminomatous testicular cancer, with both retroperitoneal and ext...
متن کاملManagement of stage I testis cancer.
OBJECTIVE Over the last 5 years the management of stage I testis cancer has changed tremendously. This review focuses on the latest changes in diagnostics and treatment of clinical stage I non-seminomatous and seminomatous germ cell tumors. METHODS A non-structured literature search (MEDLINE) was performed, including recently published papers (up to March 2006) on the subject. RESULTS Organ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Polish journal of pathology : official journal of the Polish Society of Pathologists
دوره 66 4 شماره
صفحات -
تاریخ انتشار 2015